In November, we added 101 citations in DIDB, including 51 in vitro (with 22 articles published in November 2025) and 50 in vivo articles (with 32 articles published in November 2025).
3 NDAs approved by the FDA in August and September 2025, including elamipretide (FORZINITY), imlunestrant (INLURIYO), rilzabrutinib (WAYRILZ) were also curated in DIDB.
You can check the citations that are recently published and entered in DIDB and all the NDAs/BLAs in DIDB.
As always, feel free to contact us if you have any questions or comments.